Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era

期刊论文
发表日期：

2024年5月9日

查看全文

Tetsuya Shindo,
Kohei Hashimoto,
Keiko Fujino,
Atsushi Takahashi,
Hiroshi Hotta,
Toshihiro Maeda,
Yasuharu Kunishima,
Fumimasa Fukuta,
Naoki Ito,
Atsushi Wanifuchi,
Ryuichi Kato,
Manabu Okada,
Masanori Matsukawa,
Hiroki Horita,
Akio Takayanagi,
Ko Kobayashi,
Toshiaki Tanaka,
Naoya Masumori

摘要

Purpose

To explore pre-treatment risk factors for overall survival (OS) in advanced urothelial carcinoma (UC) patients treated with first-line (1L) chemotherapy in sequential therapy (ST) era. Additionally, to evaluate the proportion of patients who were not able to undergo subsequent immune checkpoint inhibitor (ICI) therapy according to the subgroups stratified by the risk factors.

Methods

A multicenter retrospective study was conducted. Metastatic or locally advanced UC patients treated between 2017 and 2022 were included. The Kaplan–Meier method with the log-rank test and multivariate Cox regression models were used to address OS.

Results

Three hundred and fourteen patients treated with 1L chemotherapy were included in the study and 57 (18.2%) patients were not able to proceed to subsequent ICI therapy. Pre-chemotherapy risk factors for OS in 314 patients were ECOG-PS 1 or more, having no primary site resection, C-reactive protein (CRP) level of 3 mg/dL or more, and non-cisplatin-based regimen. Patients having 3 or 4 risk factors had higher risk for not being able to receive ST (Mann–Whitney U test, P < 0.001). As risk factors for OS in 230 patients who were able to receive ST, having no primary site resection, a neutrophil to lymphocyte ratio of 3 or more, and the presence of liver metastasis were identified.

Conclusion

We reported the risk factors for OS in advanced UC patients treated with 1L chemotherapy in ST era. Patients with high risk for OS may not be able to proceed to subsequent ICI therapy even in the ST era.